Asthma Budesonide / formoterol IND Dupilumab IND Masitinib Tezepelumab COPD Beclometason/formoterol/glycopyrronium Cystic fibrosis Elexacaftor / tezacaftor / ivacaftor Kaftrio is indicated in a combination regimen with ivacaftor 150mg tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene Ivacaftor IND Tezacaftor / ivacaftor IND Lung diseases other Ambrisentan IND Benralizumab IND Gefapixant Mepolizumab Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) to Nucala IND Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab). IND Pirfenidone IND Lung other Pirfenidone G